Intravitreal Bevacizumab (Avastin) for Pseudophakic Macular Edema (PME)
- Sponsor
- Asociación para Evitar la Ceguera en México
- Study ID
- NCT00406172
- Phase
- PHASE3
- Status
- Withdrawn
Conditions
- Cystoid Macular Edema
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Bevacizumab — DRUG
Study Details
To report safety and efficacy of intravitreal injection of bevacizumab in patients with cystoid macular edema secondary to cataract surgery.
Key Dates
- First listed
- Dec 4, 2006
- Start date
- Nov 30, 2006
- Status verified
- Jun 2024
- Primary completion
- Nov 30, 2006
- Completion
- Nov 30, 2006
Study Design
- Enrollment
- 0 participants (actual)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SINGLE_GROUP
Related Studies
- Therapeutic Contact Lens Drug Delivery System (TCL-DDS) in Patients With Recurrent Cystoid Macular EdemaPHASE1/PHASE2 · Recruiting · Massachusetts Eye and Ear Infirmary · Boston, Massachusetts